{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:27Z","timestamp":1792785867173,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Limburg Clinical Research Program"},{"DOI":"10.13039\/100018216","name":"ZOL","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018216","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jessa"},{"DOI":"10.13039\/501100009542","name":"Limburg Sterk Merk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009550","name":"Hasselt University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009550","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ziekenhuis Oost-Limburg and Jessa Hospital","id":[{"id":"https:\/\/ror.org\/00qkhxq50","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Scientific Research Flanders","award":["FWO1S93026N"],"award-info":[{"award-number":["FWO1S93026N"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Albuminuria is a key diagnostic and prognostic biomarker of chronic kidney disease (CKD), associated with adverse cardiovascular and renal outcomes. Despite guideline recommendations, urine albumin-to-creatinine ratio (UACR) testing is infrequently performed in cardiology. This study assessed the uptake of UACR testing, the estimated prevalence of undiagnosed albuminuria, and the use of disease-modifying therapies in patients with cardio-kidney-metabolic (CKM) disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of all adults seen at the cardiology department of a tertiary referral centre between 2019 and 2024. Data were extracted using CTcue, an AI-driven platform. Albuminuria was defined as UACR \u226530 mg\/g. A weighted logistic regression model estimated albuminuria prevalence in untested patients. Among 77 351 patients (44.8% female, mean age 64.4 years), only 8.9% had a recorded UACR, of whom 46.4% had albuminuria. Testing rates were low across high-risk groups: 29.9% in diabetes, 21.7% in heart failure, and 13.7% in hypertension. In untested patients, the predicted prevalence of albuminuria was 36.6%, and highest in those with eGFR &amp;lt;30 mL\/min\/1.73m2 (70.0%), heart failure (47.8%), or diabetes (46.8%). Use of disease-modifying therapies was low, even among patients with confirmed albuminuria. In patients with documented vs. predicted albuminuria, 43.0% vs. 39.1% received renin\u2013angiotensin system inhibitors, 12.8% vs. 5.7% received SGLT2 inhibitors, and &amp;lt;1% in both groups received finerenone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Albuminuria is substantially underdetected in cardiology practice, possibly contributing to underuse of effective CKM therapies. Systematic UACR screening with structured treatment protocols may help close this gap and improve outcomes for patients with CKM disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcag054","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:21:13Z","timestamp":1775474473000},"page":"891-900","source":"Crossref","is-referenced-by-count":1,"title":["Large-scale AI analysis reveals missed opportunities in albuminuria testing and disease-modifying therapy implementation"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8233-9967","authenticated-orcid":false,"given":"Marnicq","family":"van Es","sequence":"first","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Genk, 3600 ,","place":["Belgium"]},{"name":"Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University , Diepenbeek, 3590 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3883-4102","authenticated-orcid":false,"given":"Jonas","family":"Erzeel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Genk, 3600 ,","place":["Belgium"]},{"name":"Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University , Diepenbeek, 3590 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6235-0685","authenticated-orcid":false,"given":"Michiel","family":"De Wever","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Genk, 3600 ,","place":["Belgium"]},{"name":"Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University , Diepenbeek, 3590 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Dupont","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Genk, 3600 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7325-7734","authenticated-orcid":false,"given":"Petra","family":"Nijst","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Genk, 3600 ,","place":["Belgium"]},{"name":"Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University , Diepenbeek, 3590 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Penders","sequence":"additional","affiliation":[{"name":"Department of Clinical Biology, Ziekenhuis Oost-Limburg A.V. , Genk, 3600 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Hong Wilson","family":"Tang","sequence":"additional","affiliation":[{"name":"Center for Microbiome and Human Health, Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic , Cleveland, OH 44195 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Division of Medicine, Karolinska Institutet , Stockholm, SE-171 77 ,","place":["Sweden"]},{"name":"Heart and Vascular Center, Karolinska University Hospital , Stockholm, SE-171 77 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-9675","authenticated-orcid":false,"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[{"name":"Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University , Diepenbeek, 3590 ,","place":["Belgium"]},{"name":"Department of Nephrology, Ziekenhuis Oost-Limburg A.V. , Genk, 3600 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Martens","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Genk, 3600 ,","place":["Belgium"]},{"name":"Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University , Diepenbeek, 3590 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Mullens","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Genk, 3600 ,","place":["Belgium"]},{"name":"Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University , Diepenbeek, 3590 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"2026091606034708300_qcag054-B1","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026091606034708300_qcag054-B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091606034708300_qcag054-B3","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Writing Group for the CKD Prognosis Consortium","year":"2023","journal-title":"JAMA"},{"key":"2026091606034708300_qcag054-B4","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","journal-title":"Lancet"},{"key":"2026091606034708300_qcag054-B5","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2026091606034708300_qcag054-B6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"2026091606034708300_qcag054-B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.ajkd.2011.02.391","article-title":"High-normal albuminuria and risk of heart failure in the community","volume":"58","author":"Blecker","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2026091606034708300_qcag054-B8","doi-asserted-by":"publisher","first-page":"e2326230","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026091606034708300_qcag054-B9","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026091606034708300_qcag054-B10","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"2026091606034708300_qcag054-B11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2022","journal-title":"N Engl J Med"},{"key":"2026091606034708300_qcag054-B12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026091606034708300_qcag054-B13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091606034708300_qcag054-B14","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026091606034708300_qcag054-B15","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026091606034708300_qcag054-B16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/CIRCULATIONAHA.124.071079","article-title":"Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review","volume":"151","author":"Claudel","year":"2025","journal-title":"Circulation"},{"key":"2026091606034708300_qcag054-B17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091606034708300_qcag054-B18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jacc.2018.05.023","article-title":"Are guidelines merely suggestions?","volume":"72","author":"Jefferies","year":"2018","journal-title":"JACC"},{"key":"2026091606034708300_qcag054-B19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jacc.2022.10.028","article-title":"Albuminuria and heart failure","volume":"81","author":"Khan","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026091606034708300_qcag054-B20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026091606034708300_qcag054-B21","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.xkme.2021.04.009","article-title":"SGLT2 inhibitors and kidney and cardiac outcomes according to estimated GFR and albuminuria levels: a meta-analysis of randomized controlled trials","volume":"3","author":"Chun","year":"2021","journal-title":"Kidney Med"},{"key":"2026091606034708300_qcag054-B22","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/S0140-6736(23)00876-0","article-title":"Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in The Netherlands (THOMAS): a prospective, randomised, open-label implementation study","volume":"402","author":"Van Mil","year":"2023","journal-title":"Lancet"},{"key":"2026091606034708300_qcag054-B23","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.121.17323","article-title":"Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium","volume":"78","author":"Shin","year":"2021","journal-title":"Hypertension"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcag054\/67900975\/qcag054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/6\/891\/67900975\/qcag054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/6\/891\/67900975\/qcag054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:03:52Z","timestamp":1789553032000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/12\/6\/891\/8618017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,4,7]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcag054","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,4,7]]}}}